April 3, 2024 – Talk Bio

Genmab Acquires ProfoundBio for $1.8 Billion to Challenge AbbVie’s Elahere in ADC Market

1 year ago talkbio0Tagged AbbVie's, Acquisition (action), Antibody-Drug Conjugates, competition, Elahere, FOLR1 gene, FOLR1 protein, human, Genmab, Midphase clinical trials, ProfoundBio, Rina-S, Rinatabart sesutecan

Genmab, ProfoundBio, $1.8 billion acquisition, Antibody Drug Conjugates (ADCs), Competition with AbbVie’s Elahere, Rinatabart sesutecan (Rina-S), Folate Receptor Alpha (FRα), Midphase clinical trials

Diagonal Therapeutics Secures $128 Million Funding to Target Rare Diseases

1 year ago talkbio0Tagged Antibodies, Blue-chip, Chronic anemia, Diagonal, Merck's, Orphan disease treatment, Rare diseases focus, research, Winrevair

Diagonal Therapeutics, Antibody biotech, $128 million funding, Rare diseases focus, Orphan disease treatment, Chronic anemia, Merck’s Winrevair related research, Blue-chip investors

Vanda’s Fanapt Secures Second FDA Approval for Treating Bipolar I Disorder

1 year ago talkbio0Tagged acute, Bipolar I disorder, Dentatorubral-Pallidoluysian Atrophy, Fanapt, iloperidone, Manic, mixed episodes, United States Food and Drug Administration, Vanda Pharmaceuticals

Fanapt, Vanda Pharmaceuticals, Bipolar I Disorder, Second FDA Nod, Iloperidone, Acute Treatment of Manic or Mixed Episodes